Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Regeneron's Cholesterol Drug to Get a Closer Look


The biotech's stock has more than doubled this year on success of an eye drug but an LDL-lowering treatment should begin attracting attention if study results hold up.

Shares of Regeneron Pharmaceuticals (REGN) have more than doubled this year on a successful early sales launch of the company's drug Eylea to treat blindness in the elderly.

But a study to be presented Monday may give investors hope for a another potentially big drug from the company. Regeneron is presenting data from a study of a cholesterol-lowering therapy. The treatment, known as REGN727, is part of a new class of drugs aimed at lowering bad LDL cholesterol levels. These new drugs are considered promising as some patients can't lower LDL levels by simply taking statin medicines such as Pfizer's (PFE) Lipitor.

Regeneron and partner Sanofi (SNY) are in a race with a number of companies also working on new cholesterol drugs, including Pfizer, Amgen (AMGN), Merck (MRK), Bristol-Myers Squibb (BMY), Isis Pharmaceuticals (ISIS), and Alnylam Pharmaceuticals (ALNY).

But Regeneron is farthest along in its research and plans later this year to begin the last of three phases of studies usually needed to win US drug approval. If Monday's results are positive, investors should take note.

More than 70 million Americans have elevated levels of LDL, and almost half of them are receiving some sort of treatment, says Robert W. Baird analyst Christopher Raymond.

"A sizable market for an add-on therapy … clearly exists," Raymond says. Regeneron's drug is "emerging as an important value-driver" for the stock, he adds.

These drugs being studied by Regeneron and others seek to block a protein known as PCSK9. Early results have shown success in reaching their goals, including preliminary analysis released by Regeneron in November. REGN727 will be the focus of two presentations at the American College of Cardiology conference in Chicago, which begins this weekend. But the key presentation will be the so-called late breaker on Monday morning.

To be sure, Regeneron is years away from actually getting to the point where it would apply for US approval of its cholesterol drugs and there are plenty of things that can trip it up, such as safety issues. But Monday's results should at least give investors an early signal on the experimental treatment.

For the time being, the company continues to benefit from Elyea, which has exceeded expectations in its short time on the market. (See Regeneron Blows Away Sales Forecast for New Eye Drug.)

The company's stock fell almost 1% to $116.47 in late-morning trading Thursday. The shares are up 111% this year and 193% over the past 12 months.

Twitter: @brettchase

Follow the markets all day every day with a FREE 14 day trial to Buzz & Banter. Over 30 professional traders share their ideas in real-time. Learn more.
< Previous
  • 1
Next >
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos